Impax Laboratories, Inc. (IPXL)

Seite 1 von 1
neuester Beitrag: 25.04.21 02:55
eröffnet am: 23.01.17 16:40 von: Chalifmann3 Anzahl Beiträge: 10
neuester Beitrag: 25.04.21 02:55 von: Antjezsfga Leser gesamt: 2392
davon Heute: 1
bewertet mit 0 Sternen

23.01.17 16:40

21490 Postings, 5329 Tage Chalifmann3Impax Laboratories, Inc. (IPXL)

*Impax Laboratories is set to benefit from CVS selling its 2-pack generic version of the Adrenaclick pen for only $110.

*Impax stock has a low valuation from the recent steep sell-off.

*Impax is expected to be profitable in 2017, which will help catalyze the stock.

The controversy over Mylan (NASDAQ:MYL) raising the price of EpiPens to over $600 for a 2-pack created a need for lower-cost epinephrine injectors. Many of those who are susceptible to anaphylactic emergencies tend to keep a few injectors around because you never know when an emergency will occur or how much epinephrine you'll need to relieve the symptoms. Twenty-five percent of those with food allergies require a second dose of epinephrine. Therefore, doctors will recommend those with severe food allergies to carry 2 injectors. Those who have children with the condition are likely to keep more. For example, in many cases, a student will have to keep one or two EpiPens with their teacher and another one or two with the school nurse while keeping one or more at home.

Any unused medicine eventually expires, so there is an ongoing need to purchase epinephrine injectors even if they are not used. This high cost has consumers looking for less expensive alternatives. Recently, CVS Health (NYSE:CVS) announced that they will sell a generic version of Amedra Pharmaceuticals' Adrenaclick epinephrine injector pen for only $109.99 for a 2-pack. Impax Laboratories (NASDAQ:IPXL) is set to benefit as the company produces the generic version of Adrenaclick.

I think CVS Health's decision to sell a lower cost epinephrine injector will have a ripple effect with other pharmacies following suit to remain competitive. CVS has over 9,600 pharmacy locations, which will act as a large distribution system for Impax Laboratories' generic epinephrine injector pen. This large retail distribution system will bring more awareness for the generic product, thus boosting Impax's revenue.  

23.01.17 16:42

21490 Postings, 5329 Tage Chalifmann3Profil

Kurs historisch sehr niedrig,ich beobachte Impax Labs seit 10 Jahren,aber die waren mir immer zu teuer,jetzt heisst es abetr kaufen !

Impax Laboratories, Inc., a specialty pharmaceutical company, develops, manufactures, and markets bioequivalent pharmaceutical products. It operates in two segments, Impax Generics and Impax Specialty Pharma. The Impax Generics segment provides generic pharmaceutical products directly to wholesalers, large retail drug chains, and others; generic prescription products through third-party pharmaceutical entities pursuant to alliance and collaboration agreements; generic pharmaceutical over-the-counter (OTC) and prescription products to third parties; and generic pharmaceutical OTC products through third-party pharmaceutical companies pursuant to alliance, collaboration, and supply agreements. The Impax Specialty Pharma segment focuses on the development and promotion through its specialty sales force of proprietary brand pharmaceutical products for the treatment of central nervous system disorders, including migraine, multiple sclerosis, Parkinson’s disease, and postherpetic neuralgia. The company markets and sells its products to drug wholesalers, warehousing chain drug stores, mass merchandisers, and mail-order pharmacies in the continental United States and the Commonwealth of Puerto Rico. Impax Laboratories, Inc. has a strategic alliance agreement with Teva Pharmaceuticals Curacao N.V to develop, manufacture, and distribute controlled release generic pharmaceutical products. The company was founded in 1993 and is headquartered in Hayward, California.  

23.01.17 19:04

844 Postings, 2203 Tage goalgetterwieso Impax

Wieso beschäftigst du dich mit einem so kleinen Hersteller? Wäre es dann nicht interessanter sich mit TEVA zu beschäftigen?  

23.01.17 19:13

21490 Postings, 5329 Tage Chalifmann3klar

hey,Impax ist das grösste,was ich bisher im Biotechdepot hatte ! Gefallen mir einfach,TEVA mit 30 MRD Schulden und 35 MRD Börsenwert sind mir einfach zu konservativ ..........  

23.01.17 19:18

21490 Postings, 5329 Tage Chalifmann3hörmal

ich hab mich sogar schon intensiv mit dem noch kleineren Hersteller Supernus Pharmaceuticals (SUPN) beschäftigt,schau mal wie der läuft (im Gegensatzu zu Teva),aber die sind mir einfach zu teuer,um da einen Thread aufzumachen,mal sehen .....  

23.01.17 19:21

21490 Postings, 5329 Tage Chalifmann3junge

mit TEVA hättest du dich vor 20 Jahren beschäftigen sollen !!!! Wie willst du jetzt noch von der Aktie profitieren,oder willst du einen Call/Put Schein kaufen ?  

24.01.17 12:35

21490 Postings, 5329 Tage Chalifmann3hi

Interessant ist sicher auch noch der irische Generikaplayer Endo international (ENDP),noch brutaler abgestürzt,grösser,aber die haben 8 MRD Schulden .......


24.01.17 12:38

21490 Postings, 5329 Tage Chalifmann3und natürlich

Valeant Pharmaceuticals (VRX) bleibt sehr interessant,die verkoppen grade jede Menge Assets,um von den 30 MRD debt bis 2018 deutlich runterzukommen,solange die keine Core-assets verkaufen,bin ich bei diesem Kurs dabei .....  

25.01.17 12:24

844 Postings, 2203 Tage goalgetterWerte

Du bist schon recht aggressiv mit deinen Werten unterwegs . Bin hier deutlich konservativer . Wenn Teva unter die 30 geht werde ich anfangen zu kaufen . Sieh dir den KGV an das sind Kaufkurse.  

01.02.17 18:08

21490 Postings, 5329 Tage Chalifmann3hi goalgetter

läuft doch ! Impax läuft und Teva nicht .......  

   Antwort einfügen - nach oben